FzioMed raises $10 million:
This article was originally published in Clinica
FzioMed has raised $10 million through a private placement, enabling it to advance development of its Oxiplex adhesion barrier technology and accelerate European sales plans. Oxiplex is the San Luis Obispo, California-based company's patented polymer technology, which is aimed at a range of targeted medical applications and markets. Oxiplex was recently granted CE mark certification for use in spine, abdominal and pelvic surgery.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.